SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending following reports that President Trump declared the conflict with Iran "very complete" and "ahead of schedule," triggering a significant market rally and a sharp reversal in oil prices from recent highs. The community is intensely debating whether these comments are genuine peace signals or a strategic market manipulation, leaving many skeptical about the true resolution of the conflict and the market's future direction.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is surging, fueling a significant short squeeze, after reports of President Trump's optimistic statements suggested the Iran war is 'very complete, pretty much,' leading to a market rebound and a sharp drop in oil prices amid divided investor sentiment.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending after reporting strong quarterly results driven by significant MIPLYFFA revenue, which exceeded expectations and signals a commercial breakthrough, fueling community discussions around future profitability, anticipated European approval, and the impact of a new CFO hire.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is highly volatile amid escalating Middle East tensions threatening global oil supply, while conflicting statements from former President Trump suggesting the conflict is "very complete" are causing sharp, contentious reversals. The market remains deeply divided on whether sustained geopolitical risks will outweigh potential de-escalation and strategic reserve releases.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending as investors weigh its upcoming earnings and potential nuclear awards against a backdrop of increasing demand for AI data center power. This creates a split in community sentiment between long-term bullishness for its advanced nuclear technology and skepticism over its pre-revenue status.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is gaining attention following a new DOE agreement for its IMSR Fuel Salt production pilot and recent positive analyst coverage with a $15 price target. The community actively discusses its Integral Molten Salt Reactor technology as a "dark horse" in the advanced nuclear sector, comparing its potential to peers like OKLO, especially given its strategic position to meet escalating AI data center energy demands.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

AN2 Therapeutics is seeing an explosive rally and volume spike, driven by a recently announced $40 million private placement. This has ignited speculation of a short squeeze among bulls, though bears are quick to point out the offering's significantly lower per-share price, raising concerns about dilution and sustainability.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

Relmada Therapeutics is trending sharply higher after reporting positive 12-month Phase 2 interim data for its bladder cancer candidate NDV-01, coupled with an oversubscribed $160 million private financing; the community is actively debating its strong momentum and future potential against concerns of dilution.

Aureus Greenway Holdings, Inc. engages in the ownership and operation of public golf country clubs, namely Kissimmee Bay Country Club and Remington Golf Club. It operates through the following segments: Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental, Membership Dues, Food and Beverage Services, and Ancillary Services and Amenities. The Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental segment is involved in the collection of fees for every round of eighteen holes, provision of driving ranges for practice, sale of golf apparel and equipment, and rental of golf products and cars. The Membership Dues segment refers to the membership fees for customers to access the club's facilities and services for a set period or daily at the point of sale. The Food and Beverage Services segment provides culinary services such as catering. The Ancillary Services and Amenities segment offers leisure activities hosted in an on-premises clubhouse, kitchen, bar, and dining area. The company was founded on December 22, 2023 and is headquartered in Kissimmee, FL.

Aureus Greenway Holdings Inc.

Aureus Greenway Holdings ($AGH) is trending due to its merger with drone manufacturer Powerus, a company backed by Eric Trump and Donald Trump Jr., which is pivoting it into the U.S. drone and defense sector; the community is actively discussing the potential for significant government contracts amid efforts to replace Chinese drone technology.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as escalating geopolitical tensions, particularly concerning a potential conflict involving Iran and its impact on rising oil prices, are driving widespread market fear and discussions of increased volatility. The community is actively debating whether to accumulate UVIX as a hedge against a market correction or if these events are already priced into the market amid perceived manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lineage Cell (LCTX) Reports Break-Even Earnings for Q4

Lineage Cell (LCTX) delivered earnings and revenue surprises of +100.00% and +187.81%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates

Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of +13.39% and -63.64%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Lags Q4 Earnings and Revenue Estimates

Pacira (PCRX) delivered earnings and revenue surprises of -32.74% and -0.06%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration

Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration PR Newswire VANCOUVER...

Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates

Lineage Cell (LCTX) delivered earnings and revenue surprises of -550.00% and +40.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Wave Life Sciences (WVE): Can Its 11.4% Jump Turn into More Strength?

Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Lineage Cell (LCTX) Reports Q2 Loss, Beats Revenue Estimates

Lineage Cell (LCTX) delivered earnings and revenue surprises of +50.00% and +75.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates

Nuvation Bio (NUVB) delivered earnings and revenue surprises of 0.00% and +93.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Brookdale Senior Living (BKD) Reports Q2 Loss, Misses Revenue Estimates

Brookdale (BKD) delivered earnings and revenue surprises of -28.57% and -0.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.01	--	--	N/A
Q4 '25	-$0.04	$0.00	109.33%	BEAT
Q3 '25	-$0.03	-$0.13	-405.56%	MISSED
Q2 '25	-$0.03	-$0.13	-387.49%	MISSED
Q1 '25	-$0.03	-$0.02	22.22%	BEAT

LCTX
Lineage Cell Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest LCTX News

LCTXLineage Cell Therapeutics Inc